- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- hexemb.io
- Total Funding
- $17.9M
- Last Round
- $10.4M SeedApr 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
heXembio is a longevity therapeutics company developing the world's first rejuvenated hematopoietic stem cell therapy. Its platform restores the regenerative power of aged blood stem cells using a synthetic biology approach validated in peer-reviewed research published in Nature. The technology targets aging, immune health, and hematological conditions.
Summary
heXembio is a Biotech company based in New York, United States, founded in 2024. It has raised $17.9M in total across 2 rounds, most recently a $10.4M Seed round in Apr 2026. Investors include Draper Associates, SOSV and Zentynel.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Apr 2026
Sign up to see all 2 events
Funding: Seed. Amounts, valuations, and investors where available.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/hexembio"><img src="https://indexed.vc/api/badge/company/hexembio" alt="heXembio on Indexed.vc" width="260" height="76" /></a>